Estrella Immunopharma, Inc.
Support and Resistance Levels
Past performance
News About ESLA
All events for ESLA
All deals for ESLA
Financial Ratios
Financial Statements
ESLA vs Sector & Peers
About Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California. Website estrellabio.com
Headquarters EmeryVille, CA, US